BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24043582)

  • 1. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.
    Ito Y; Miyamoto T; Kamimura T; Takase K; Henzan H; Sugio Y; Kato K; Ohno Y; Eto T; Teshima T; Akashi K
    Int J Hematol; 2013 Oct; 98(4):463-71. PubMed ID: 24043582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
    Abou-Nassar KE; Stevenson KE; Antin JH; McDermott K; Ho VT; Cutler CS; LaCasce AS; Jacobsen ED; Fisher DC; Soiffer RJ; Alyea EP; Koreth J; Freedman AS
    Bone Marrow Transplant; 2011 Dec; 46(12):1503-9. PubMed ID: 21258420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
    Yano S; Mori T; Kanda Y; Kato J; Nakaseko C; Fujisawa S; Tomita N; Sakai R; Shono K; Saitoh T; Aotsuka N; Kobayashi N; Saito T; Takahashi S; Kanamori H; Okamoto S;
    Bone Marrow Transplant; 2015 Oct; 50(10):1299-305. PubMed ID: 26168068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
    Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
    Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
    Ono Y; Mori T; Kato J; Yamane A; Shimizu T; Kikuchi T; Kohashi S; Okamoto S
    Am J Hematol; 2012 Sep; 87(9):929-31. PubMed ID: 22674621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation for follicular lymphoma: optimal timing and indication.
    Kim SW
    J Clin Exp Hematop; 2014; 54(1):39-47. PubMed ID: 24942945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
    Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
    Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Avivi I; Montoto S; Canals C; Maertens J; Al-Ali H; Mufti GJ; Finke J; Schattenberg A; Fanin R; Cornelissen JJ; Vernant JP; Russell N; Beguin Y; Thomson K; Verdonck LF; Kobbe G; Tilly H; Socié G; Sureda A;
    Br J Haematol; 2009 Dec; 147(5):719-28. PubMed ID: 19793383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 15. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
    Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
    Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
    Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.